US 12,305,241 B2
EML4-ALK translocations in lung cancer
Heather R. Sanders, Winchester, CA (US); Maher Albitar, Coto De Caza, CA (US); and Aurelia Meloni-Ehrig, Gainesville, VA (US)
Assigned to Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed by Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed on May 1, 2023, as Appl. No. 18/141,862.
Application 15/952,424 is a division of application No. 14/928,347, filed on Oct. 30, 2015, granted, now 9,957,573.
Application 18/141,862 is a continuation of application No. 16/594,718, filed on Oct. 7, 2019, granted, now 11,639,529.
Application 16/594,718 is a continuation of application No. 15/952,424, filed on Apr. 13, 2018, granted, now 10,435,758.
Application 14/928,347 is a continuation of application No. 13/518,232, granted, now 9,175,350, previously published as PCT/US2010/060858, filed on Dec. 16, 2010.
Claims priority of provisional application 61/301,551, filed on Feb. 4, 2010.
Claims priority of provisional application 61/289,234, filed on Dec. 22, 2009.
Prior Publication US 2023/0416835 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2537/143 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/16 (2013.01)] 8 Claims
 
1. A method for determining the EML4-ALK gene fusion variant status in a subject comprising:
(a) obtaining a biological sample from a subject suspected of having or having a neoplastic disorder;
(b) extracting nucleic acids from the biological sample to generate an isolated nucleic acid sample;
(c) performing a multiplex reaction to amplify a plurality of nucleic acids in the isolated nucleic acid sample using oligonucleotide primers that bind to exons 1-22 of EML4 and exon 20 of ALK, wherein the oligonucleotide primers comprise at least 22 forward primers selected from SEQ ID NOs: 3-24; and
(d) detecting the presence or absence of a EML4-ALK gene fusion variant in the amplified nucleic acids.